StockNews.AI
SRPT
StockNews.AI
188 days

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

1. Sarepta Therapeutics will announce Q4 and full-year 2024 results on Feb. 26, 2025. 2. A conference call will follow the results at 4:30 p.m. E.T. 3. They lead in precision genetic medicine for rare diseases, focusing on DMD and LGMD. 4. With over 40 programs in development, their pipeline is robust and expansive. 5. Investor information is regularly updated on their website for transparency.

Earnings
-0.06%Current Return
VS
+1.64%S&P 500
$109.7202/12 08:48 AM EDTEvent Start
$109.6502/13 02:59 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results might show growth in pipeline programs, positively impacting SRPT's valuation. For instance, positive earnings reports often lead to upward price movements for biotech firms.

How important is it?

Earnings reports from Sarepta are critical for assessing company performance; positive news can boost stock prices significantly.

Why Short Term?

The immediate impact is likely around the Q4 report date, influencing investor sentiment short-term, as seen in previous earnings announcements.

Related Companies

SRPT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 26, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Related News